

# CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL

RECEIVED

MAR 24 2000

Submit an original, and a duplicate for fee processing.

(Only for Continuation or Divisional applications under 37 CFR 1.53(d))

Address to: Assistant Commissioner for Patents Box CPA Washington, DC 20231	Attorney Docket No.  DM-6864-A	TECH CENTER 1500/24907
	First Named Inventor	He et al.
	Express Mail Label No.	EL502307999US
	Express Mailing Date	March 21, 2000

This is a request for a ☒ continuation or ☐ divisional application under 37 CFR 1.53(d), (continued prosecution application (CPA)) of prior application number 09/015,002, filed on January 28, 1998, entitled Azolotriazines and Pyrimidines.

## NOTES

**FILING QUALIFICATIONS:** The prior application identified above must be a non-provisional application that is either: (1) complete as defined by 37 CFR 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371.

**C-I-P NOT PERMITTED:** A continuation-in-part application cannot be filed as A CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 1.53(b).

**EXPRESS ABANDONMENT OR PRIOR APPLICATION:** The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

**ACCESS TO PRIOR APPLICATION:** The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application in the file jacket.

**35 U.S.C. 120 STATEMENT:** In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(a).

1. ☐ Enter the unentered amendment previously filed on \_\_\_\_\_ under 37 CFR 1.116 in the prior non-provisional application.
2. ☒ A preliminary amendment is enclosed.
3. ☐ This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4). DELETE the following inventor(s) named in the prior non-provisional application:
4. ☐ A new power of attorney or authorization of agent is enclosed.
5. Information Disclosure Statement (IDS) is enclosed:
  - a. ☐ Cover Letter and PTO-1449
  - b. ☐ Copies of IDS Citations
6. ☒ Return Receipt Postcard (MPEP 503)

Please type a plus sign (+) inside this box →

PTO/SB/29  
As modified by DuPont Pharmaceuticals Company  
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

CLAIMS	(1) FOR	(2) NUMBER FIELD	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	<b>TOTAL CLAIMS</b> (37 CRR 1.16(C))	- ( ) =		x \$ ( ) =	<b>RECEIVED</b>  MAR 24 2000  TECH CENTER 1600/2800
	<b>INDEPENDENT CLAIMS</b> (37 CFR 1.16(b))	- ( ) =		x \$ ( ) =	
	<b>MULTIPLE DEPENDENT CLAIM(S)</b> (if applicable)				
				<b>BASIC FEE</b> (37 CFR 1.16(a))	\$690.00
				<b>TOTAL =</b>	\$690.00

7. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 04-1928:

a. ☐ Fees required under 37 CFR 1.16.

b. ☒ Fees required under 37 CFR 1.17

8. ☐ Other:

9. Priority of foreign application no. \_\_\_\_\_ filed on \_\_\_\_\_ in \_\_\_\_\_ is

☐ ☐ (country)


claimed under 35 U.S.C. 119.

10. Other papers enclosed: \_

#### 11. CORRESPONDENCE ADDRESS

NAME	Kenneth B. Rubin				
ADDRESS	1007 Market Street				
CITY	Wilmington	STATE	Delaware	ZIP CODE	19898
COUNTRY	U.S.A.	TELEPHONE	302-992-3215	FAX	302-992-6659

#### 12. SIGNATURE OF ATTORNEY OR AGENT REQUIRED

NAME	Kenneth B. Rubin	REG. NO.: 36,259
SIGNATURE		
DATE	March 21, 2000	